Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
AJNR Am J Neuroradiol ; 43(5): 650-660, 2022 05.
Article En | MEDLINE | ID: mdl-34620594

Small vessel disease, a disorder of cerebral microvessels, is an expanding epidemic and a common cause of stroke and dementia. Despite being almost ubiquitous in brain imaging, the clinicoradiologic association of small vessel disease is weak, and the underlying pathogenesis is poorly understood. The STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) criteria have standardized the nomenclature. These include white matter hyperintensities of presumed vascular origin, recent small subcortical infarcts, lacunes of presumed vascular origin, prominent perivascular spaces, cerebral microbleeds, superficial siderosis, cortical microinfarcts, and brain atrophy. Recently, the rigid categories among cognitive impairment, vascular dementia, stroke, and small vessel disease have become outdated, with a greater emphasis on brain health. Conventional and advanced small vessel disease imaging markers allow a comprehensive assessment of global brain heath. In this review, we discuss the pathophysiology of small vessel disease neuroimaging nomenclature by means of the STRIVE criteria, clinical implications, the role of advanced imaging, and future directions.


Cerebral Small Vessel Diseases , Stroke , Brain/diagnostic imaging , Brain/pathology , Cerebral Small Vessel Diseases/diagnostic imaging , Cerebral Small Vessel Diseases/pathology , Humans , Magnetic Resonance Imaging/methods , Neuroimaging/methods , Radiologists , Stroke/pathology
2.
AJNR Am J Neuroradiol ; 42(6): 1008-1016, 2021 06.
Article En | MEDLINE | ID: mdl-33707278

PURPOSE: Our aim was to study the association between abnormal findings on chest and brain imaging in patients with coronavirus disease 2019 (COVID-19) and neurologic symptoms. MATERIALS AND METHODS: In this retrospective, international multicenter study, we reviewed the electronic medical records and imaging of hospitalized patients with COVID-19 from March 3, 2020, to June 25, 2020. Our inclusion criteria were patients diagnosed with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection with acute neurologic manifestations and available chest CT and brain imaging. The 5 lobes of the lungs were individually scored on a scale of 0-5 (0 corresponded to no involvement and 5 corresponded to >75% involvement). A CT lung severity score was determined as the sum of lung involvement, ranging from 0 (no involvement) to 25 (maximum involvement). RESULTS: A total of 135 patients met the inclusion criteria with 132 brain CT, 36 brain MR imaging, 7 MRA of the head and neck, and 135 chest CT studies. Compared with 86 (64%) patients without acute abnormal findings on neuroimaging, 49 (36%) patients with these findings had a significantly higher mean CT lung severity score (9.9 versus 5.8, P < .001). These patients were more likely to present with ischemic stroke (40 [82%] versus 11 [13%], P < .0001) and were more likely to have either ground-glass opacities or consolidation (46 [94%] versus 73 [84%], P = .01) in the lungs. A threshold of the CT lung severity score of >8 was found to be 74% sensitive and 65% specific for acute abnormal findings on neuroimaging. The neuroimaging hallmarks of these patients were acute ischemic infarct (28%), intracranial hemorrhage (10%) including microhemorrhages (19%), and leukoencephalopathy with and/or without restricted diffusion (11%). The predominant CT chest findings were peripheral ground-glass opacities with or without consolidation. CONCLUSIONS: The CT lung disease severity score may be predictive of acute abnormalities on neuroimaging in patients with COVID-19 with neurologic manifestations. This can be used as a predictive tool in patient management to improve clinical outcome.


Brain/diagnostic imaging , COVID-19/diagnostic imaging , COVID-19/pathology , Lung/diagnostic imaging , Adult , Aged , Brain/pathology , COVID-19/complications , Humans , Lung/pathology , Magnetic Resonance Imaging/methods , Male , Middle Aged , Neuroimaging , Prevalence , Retrospective Studies , SARS-CoV-2 , Severity of Illness Index , Tomography, X-Ray Computed/methods
3.
Article En | MEDLINE | ID: mdl-19963508

Therapeutic benefits of subthalamic nucleus (STN) deep brain stimulation (DBS) for motor symptoms of Parkinson's disease (PD) are well-documented. However, the mechanisms underlying motor improvement with DBS remain poorly understood. We tested the hypothesis that STN-DBS-related improvements in voluntary arm movement kinematics are mediated by changes in the velocity and temporal sequencing of proximal joint angles. We evaluated a 56 year old male and 66 year old female with idiopathic Parkinson's disease chronically implanted with bilateral STN-DBS. Patients performed a button press task while off medication in the DBS-on and DBS-off conditions. Movements of the upper limb were recorded using a 3D motion analysis system, and detailed kinematic measures were obtained for the arm and forearm. As expected, reaction and movement times were improved in the DBS-on compared to DBS-off condition. The two subjects differed with regards to the magnitude of their changes in peak linear velocity and peak angular velocities (shoulder flexion extension, shoulder abduction adduction and elbow flexion extension). Surprisingly, both PD patients increased the frequency with which they used a preferred sequence of shoulder and elbow joint activations when in the DBS-on condition. This preferred pattern was adopted with twice the frequency than in the DBS-off condition, and with increased frequency relative to a control group of 9 age-matched controls. These results suggest that STN-DBS may improve movement execution at the cost of flexibility in movement execution strategy.


Arm/physiology , Biomechanical Phenomena , Deep Brain Stimulation , Parkinson Disease/therapy , Aged , Female , Humans , Male , Middle Aged , Parkinson Disease/physiopathology
...